SCHEMBL6502791

SCHEMBL6502791

Fc1c[nH]c2ncncc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA5 O75582 1/20 0.45
CDK2 P24941 2/20 0.37
CDC7 O00311 1/20 0.37
CCNT1 O60563 1/20 0.37
CCNE1 P24864 1/20 0.37
CDK9 P50750 1/20 0.37
DBF4 Q9UBU7 1/20 0.37
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
NUDT1 P36639 1/20 0.35
TBK1 Q9UHD2 2/20 0.34
LATS1 O95835 1/20 0.34
NTRK1 P04629 5/20 0.33
MAP3K12 Q12852 1/20 0.32
IRAK4 Q9NWZ3 2/20 0.32
MKNK2 Q9HBH9 2/20 0.32
MKNK1 Q9BUB5 1/20 0.32
GSK3B P49841 3/20 0.32
TRPA1 O75762 3/20 0.31
IKBKE Q14164 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1085884 0.75 AXL (0.55) RPS6KA5CDK2CCNT1CDK9TBK1
SCHEMBL29598321 0.75 RPS6KA5 (0.45) RPS6KA5PRMT5WDR77TBK1LATS1
SCHEMBL21903027 0.75 RPS6KA5 (0.57) RPS6KA5CDC7CDK9PRMT5WDR77
SCHEMBL2619224 0.75 RPS6KA5 (0.45) RPS6KA5PRMT5WDR77TBK1LATS1
SCHEMBL311676 0.75 RPS6KA5 (0.45) RPS6KA5CDK2TBK1LATS1NTRK1
SCHEMBL23571474 0.75 RPS6KA5 (0.45) RPS6KA5CDK2CDC7CCNT1CCNE1
SCHEMBL14237884 0.75 RPS6KA5 (0.45) RPS6KA5CDK2CDC7CCNT1CCNE1
SCHEMBL22264317 0.75 RPS6KA5 (0.42) RPS6KA5PRMT5WDR77MAP3K12IRAK4
SCHEMBL14236205 0.72 RPS6KA5 (0.47) RPS6KA5CDK2CDC7CCNT1CCNE1
SCHEMBL1093381 0.72 RPS6KA5 (0.43) RPS6KA5TBK1LATS1NTRK1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250134869-A1 Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides PFIZER INC (US) 2025-05-01 US disclosed
CN-112805006-B PRMT5 inhibitors 默沙东有限责任公司 2024-09-24 CN disclosed
US-12077533-B2 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides PFIZER INC. (US) 2024-09-03 US disclosed
CN-111712498-B Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors 鲁平有限公司 2023-09-29 CN disclosed
CN-113614087-B WEE1 inhibitor and preparation and application thereof 首药控股(北京)股份有限公司 2023-06-02 CN disclosed
US-20230009153-A1 PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES PFIZER INC. (US) 2023-01-12 US disclosed
CN-110003216-A E1 activating enzyme inhibitors 千禧药品公司 2019-07-12 CN disclosed
CN-106008512-B E1 activating enzyme inhibitors 千禧药品公司 2019-03-12 CN disclosed
CN-106008512-A INHIBITORS OF E1 ACTIVATING ENZYMES 千禧药品公司 2016-10-12 CN disclosed
CN-101379061-B E1 activating enzyme inhibitor 千禧药品公司 2016-06-15 CN disclosed
CN-103288835-A Inhibitors of E1 activating enzyme MILLENNIUM PHARM INC 2013-09-11 CN disclosed
CN-101379061-A E1 activating enzyme inhibitor MILLENNIUM PHARM INC (US) 2009-03-04 CN disclosed
WO-2005016878-A3 METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS ISIS PHARMACEUTICALS INC (US) 2005-06-02 WO disclosed
WO-2005016878-A3 METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS ISIS PHARMACEUTICALS INC (US) 2005-06-02 WO disclosed
WO-2005016878-A2 METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2005-02-24 WO disclosed
WO-2005016878-A2 METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2005-02-24 WO disclosed
WO-2005016878-A2 METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12077533-B2 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides ACR, PKD2, PGA5 RPS6KA5 2206/4885CDK2 298/4885CDC7 2447/4885
US-20250134869-A1 Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides JAK2, JAK3, JAK1 RPS6KA5 569/4885CDK2 10/4885CDC7 1074/4885
US-20230009153-A1 PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES JAK2, JAK3, JAK1 RPS6KA5 655/4885CDK2 5/4885CDC7 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.